Project Grant HT9425261E037
Award Date 6/1/26
Completion Date 5/31/30
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $560K project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop novel digenic combination therapies for pancreatic cancer treatment. The award, effective September 1, 2026, through August 31, 2028, supports a two-year research initiative focused on advancing therapeutic development and translational research in oncology. As a leading...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1,099,614 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research defining a retinoblastoma (RB) functional subtype of endometrial cancer. The award, effective from June 1, 2026 through May 31, 2030, supports hypothesis-driven biomedical research aimed at advancing cancer treatment and detection through innovative...
- FEDERAL GRANT AWARD SUMMARY The Defense Health Agency (DHA) awarded President and Fellows of Harvard College, operating through Harvard Medical School, a $1.352 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, through July 31, 2029. The award supports research focused on targeted therapy development through spatial molecular profiling for rare pediatric and adult brain tumors using limited tissue samples. This research...
- The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research aimed at understanding and therapeutically targeting treatment-emergent neuroendocrine prostate cancer. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
- The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
- The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
- The Defense Health Agency awarded a $524,664 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) through the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, which runs from December 1, 2024 to November 30, 2026, will fund research into the "Mechanisms of Irisin-Induced Cognitive Benefit in PD." DFCI, a prestigious non-profit cancer research center in Boston, will leverage its expertise in areas like oncology, immunology, and...